Morton Collins joins Formula board
This article was originally published in Scrip
Oncology drug development company Formula Pharmaceuticals has appointed Morton Collins to its board of directors. Mr Collins was the founder and CEO of Data Science Ventures earlier in his career, as well as the founder and managing partner of DSV Associates, DSV Partners III and DSV Partners IV.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.